Replimune Group Inc
NASDAQ:REPL

Watchlist Manager
Replimune Group Inc Logo
Replimune Group Inc
NASDAQ:REPL
Watchlist
Price: 10.18 USD -1.93% Market Closed
Market Cap: 784m USD

Relative Value

There is not enough data to reliably calculate the relative value of REPL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REPL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.1
Forward
30.7
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-6.8
Industry
23
Forward
-3.5
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-9.3
Industry
19.4
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-9.7
Industry
23.1
vs History
68
vs Industry
45
Median 3Y
1.9
Median 5Y
2.2
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
Forward
14.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
vs Industry
27
Median 3Y
-2.6
Median 5Y
-4.1
Industry
4.4
Forward
-1.5
vs History
vs Industry
26
Median 3Y
-2.5
Median 5Y
-4.1
Industry
4.5
Forward
-1.4
vs History
vs Industry
30
Median 3Y
-3.3
Median 5Y
-5.5
Industry
5.2
vs History
vs Industry
25
Median 3Y
-3.2
Median 5Y
-5.3
Industry
3.7
vs History
71
vs Industry
26
Median 3Y
7.8
Median 5Y
9.3
Industry
4.8

Multiples Across Competitors

REPL Competitors Multiples
Replimune Group Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Replimune Group Inc
NASDAQ:REPL
784.7m USD 0 -3.2 -1.4 -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 706 638.2 -164 955.5 -200 308.6 -198 022.8
US
Abbvie Inc
NYSE:ABBV
334.1B USD 5.8 80.4 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
155.9B USD 4.6 26.3 14.2 23.4
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD 4.9 23.6 10.2 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 10.3 -115.9 24.6 25.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 029.8 -518 -564 -549
AU
CSL Ltd
ASX:CSL
117.1B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56B USD 4 12.4 11 12.4
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60 -64.6 -58.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.7B USD 16.9 -147.3 -659.2 -330.3
P/S Multiple
Revenue Growth P/S to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average P/S: 3 470 873.9
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 706 638.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 029.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4
4%
1
US
S
Seagen Inc
F:SGT
19.6
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Replimune Group Inc
NASDAQ:REPL
Average P/E: 34.1
Negative Multiple: -3.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 955.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average EV/EBITDA: 15.4
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 308.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -659.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average EV/EBIT: 20
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 022.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -549 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -330.3 N/A N/A